

# CURE

Beyond  
**CIRM** 2.0  
CALIFORNIA'S STEM CELL AGENCY

*now it's personal*




**Gil Sambrano, Ph.D.**


Vice President Portfolio Development  
and Review

# HOPE

# Clinical Stage Programs



**CLIN 1**



**CLIN 2**



**CLIN 3**

# Scoring System for 2.0 Applications



- **Score of “1”**

*Exceptional merit and warrants funding.*

- **Score of “2”**

*Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.*

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months.***

Applications are scored by all scientific members of the GWG with no conflict.

# CLIN2-10192: Phase 1/2 Clinical Trial for B-Cell Cancers



**Therapy:** Monoclonal antibody targeting cancer stem cells

**Indication:** Lymphocytic leukemia or mantle cell lymphoma

**Goal:** Complete a phase 1b/2a clinical trial to assess safety and efficacy of the antibody therapy in patients

## **Major Proposed Activities:**

- Manufacture of monoclonal antibody
- Conduct of clinical trial

**Funds Requested:** \$18,292,674 (\$13,341,842 Co-funding)

# CLIN2-10192: Phase 1/2 Clinical Trial for B-Cell Cancers



**Budget Review:** Pass

**GWG Score:** 1 Exceptional merit and warrants funding

- Votes for score of 1: **14**
- Votes for score of 2: **0**
- Votes for score of 3: **0**

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$18,292,674\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's assessment of allowable costs and activities.

# CLIN2-10386: Phase 1 Clinical Trial for Improved Bone Marrow Engraftment



**Therapy:** Cord blood and endothelial cell therapy

**Indication:** Patients receiving myeloablation conditioning

**Goal:** Complete a phase 1b clinical trial to assess safety and efficacy of the combination cell therapy in patients

## **Major Proposed Activities:**

- Patient recruitment and enrollment
- Interim analysis of initial cohort
- Conduct of clinical trial

**Funds Requested:** \$5,000,000 (\$2,667,776 Co-funding)

# CLIN2-10386: Phase 1 Clinical Trial for Improved Bone Marrow Engraftment



**Budget Review:** Pass

**GWG Score:** 1 Exceptional merit and warrants funding

- Votes for score of 1: **13**
- Votes for score of 2: **0**
- Votes for score of 3: **0**

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$5,000,000\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's assessment of allowable costs and activities.